Compare REGN & COR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REGN | COR |
|---|---|---|
| Founded | 1988 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.6B | 68.5B |
| IPO Year | 1995 | 2001 |
| Metric | REGN | COR |
|---|---|---|
| Price | $648.67 | $298.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 14 |
| Target Price | ★ $830.16 | $390.62 |
| AVG Volume (30 Days) | 986.6K | ★ 1.4M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | 0.55% | ★ 0.77% |
| EPS Growth | ★ 8.19 | 5.71 |
| EPS | 6.75 | ★ 11.27 |
| Revenue | $5,872,227,000.00 | ★ $321,332,819,000.00 |
| Revenue This Year | $12.45 | $8.89 |
| Revenue Next Year | $10.13 | $6.75 |
| P/E Ratio | $96.34 | ★ $26.52 |
| Revenue Growth | ★ 20.82 | 9.31 |
| 52 Week Low | $541.00 | $244.82 |
| 52 Week High | $821.11 | $377.54 |
| Indicator | REGN | COR |
|---|---|---|
| Relative Strength Index (RSI) | 57.26 | 67.32 |
| Support Level | $593.21 | $296.08 |
| Resistance Level | $664.00 | $326.95 |
| Average True Range (ATR) | 14.91 | 7.37 |
| MACD | 6.95 | 2.31 |
| Stochastic Oscillator | 86.77 | 97.11 |
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.